- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | OKYO Pharma to Present at BIO-Europe 2025 in Vienna | 230 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 29, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 29.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.10. | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 16.10. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 208 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 16.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 198 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 340 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
| 16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.07. | Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie | 1 | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 207 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen | |
| 16.07. | OKYO Pharma stock surges after positive Phase 2 results for eye pain drug | 2 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 607,80 | -0,75 % | IDEXX Laboratories: Gibt es bei diesem Ausbruch ein "aber"? | IDEXX Laboratories legte gestern vor Handelsbeginn starke Quartalszahlen vor. Dadurch gelang es, das bisherige, aus dem Jahr 2021 stammende Rekordhoch bei 706,95 US-Dollar zu überwinden. Heißt es hier... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,614 | +1,64 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,018 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2025.ISIN NameCA80013R2063 SANDSTORM... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,640 | -0,60 % | Exosomen statt Viren: Warum NurExone, Regenxbio und Voyager den Markt für Nerventherapien verändern könnten | ||
| ANAVEX LIFE SCIENCES | 6,296 | -0,06 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group | ADAS-Cog13 difference -12.78 (P 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring impaired Autophagy - preceding amyloid-beta and tau NEW YORK, Oct. 29, 2025... ► Artikel lesen | |
| CELLAVISION | 14,260 | -9,52 % | CellaVision: Softer Quarter with Mixed Regional Performance | Organic sales growth:Q3, 2025: 2.6% (9.4)EBITDA margin:Q3, 2025: 28% (27)July 1st - September 30th, 2025Net sales decreased by -1.7% (6.4) to SEK 176 m (179).Sales increased organically by 2.6% (9.4)... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,300 | -0,93 % | PRECISION BIOSCIENCES INC - 10-Q, Quarterly Report | ||
| ZYMEWORKS | 14,900 | +4,20 % | Zymeworks outlines capital allocation strategy and expands ADC pipeline while targeting funding through 2027 | ||
| VTV THERAPEUTICS | 21,600 | +5,88 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 7,440 | -9,27 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results | - Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D - Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations - Orphan... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,090 | -3,99 % | Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process | BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments... ► Artikel lesen | |
| NUVATION BIO | 4,725 | -5,88 % | Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA's advice | ||
| MIRA PHARMACEUTICALS | 1,290 | +2,38 % | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,300 | -5,11 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE... ► Artikel lesen | |
| ONCONETIX | 2,600 | -11,56 % | Onconetix, Inc. - S-1, General form for registration of securities |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,195 (-7,36 %) liegt der Kurs bei 2,455 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.